136 related articles for article (PubMed ID: 36094533)
1. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
Chen L; Wang J; Wang Z
Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
[TBL] [Abstract][Full Text] [Related]
2. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
[TBL] [Abstract][Full Text] [Related]
3. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
[No Abstract] [Full Text] [Related]
4. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
[TBL] [Abstract][Full Text] [Related]
5. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
[No Abstract] [Full Text] [Related]
6. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
[TBL] [Abstract][Full Text] [Related]
8. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
Song Y; Wang J; Wang Y; Wang Z
Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
[TBL] [Abstract][Full Text] [Related]
10. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
Jin Z; Wang Y; Wei N; Wang Z
Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
[TBL] [Abstract][Full Text] [Related]
12. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Relapsed Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report.
Pi Y; Wang J; Wang Z
Infect Drug Resist; 2022; 15():3751-3756. PubMed ID: 35859915
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Yin Q; Wang J; Wang Z
Ann Hematol; 2022 Nov; 101(11):2471-2476. PubMed ID: 36071294
[TBL] [Abstract][Full Text] [Related]
15. Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection.
Ma H; Zhang L; Wei A; Yang J; Wang D; Zhang Q; Zhao Y; Chen S; Lian H; Zhang L; Zhou C; Qin M; Li Z; Wang T; Zhang R
Orphanet J Rare Dis; 2021 Jun; 16(1):269. PubMed ID: 34112210
[TBL] [Abstract][Full Text] [Related]
16. Requirement for etoposide in the initial treatment of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
Song Y; Wang Y; Wang Z
Br J Haematol; 2019 Sep; 186(5):717-723. PubMed ID: 31115044
[TBL] [Abstract][Full Text] [Related]
17. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
Xu Y; Li W; Gan J; He X; Huang X
Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
[TBL] [Abstract][Full Text] [Related]
18. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
[TBL] [Abstract][Full Text] [Related]
19. Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Shiraishi A; Ohga S; Doi T; Ishimura M; Takimoto T; Takada H; Miyamoto T; Abe Y; Hara T
Pediatr Blood Cancer; 2012 Aug; 59(2):265-70. PubMed ID: 22183955
[TBL] [Abstract][Full Text] [Related]
20. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.
Pi Y; Wang J; Zhou H; Ye X; Sun X; Liu L; Pan X; Wang Z
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3033-3041. PubMed ID: 35852619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
